ID   OSC-20
AC   CVCL_3087
SY   OSC20
DR   CLO; CLO_0009950
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 979
DR   cancercelllines; CVCL_3087
DR   Cell_Model_Passport; SIDM00565
DR   Cosmic; 1120702
DR   Cosmic; 1995604
DR   Cosmic-CLP; 1240196
DR   DepMap; ACH-001626
DR   EGA; EGAS00001000978
DR   GDSC; 1240196
DR   GEO; GSM827220
DR   GEO; GSM1670309
DR   JCRB; JCRB0197
DR   JCRB; FDSC0051
DR   LINCS_LDP; LCL-1220
DR   PharmacoDB; OSC20_1206_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3087
DR   Wikidata; Q54936583
RX   DOI=10.15114/tr.25.93;
RX   DOI=10.15114/tr.35.25;
RX   PubMed=9119748;
RX   PubMed=12716470;
RX   PubMed=19123955;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 27.4 hours (Note=At 35th passage) (DOI=10.15114/tr.25.93); 65 hours (Note=Lot 02032003), ~49 hours (Note=Lot 11152011), ~35 hours (Note=Lot 07182019) (JCRB=JCRB0197).
CC   HLA typing: A*02,11; B*46,55; C*w01,w09 (PubMed=9119748).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro81Leu (c.242C>T); ClinVar=VCV000833629; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1048Arg (c.3143A>G); ClinVar=VCV000450316; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.14%; Native American=0.23%; East Asian, North=75.72%; East Asian, South=16.66%; South Asian=0%; European, North=0%; European, South=4.24% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0051; true.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; DepMap
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8
ST   D16S539: 9,13
ST   D18S51: 13
ST   D21S11: 29,32.2
ST   D3S1358: 16
ST   D5S818: 13 (Cosmic-CLP)
ST   D5S818: 13,14 (DepMap)
ST   D7S820: 10
ST   D8S1179: 12,14
ST   FGA: 22
ST   Penta D: 9,12
ST   Penta E: 14,16
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_WW78 ! TcOSC-20
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 33
//
RX   DOI=10.15114/tr.25.93;
RA   Yokoi T., Hirata S., Nishimura F., Miyakawa A., Odajima T.,
RA   Kohama G.-i., Mochizuki Y.;
RT   "Some properties of a newly established human cell line from a oral
RT   squamous carcinoma.";
RL   Tumor Res. 25:93-103(1990).
//
RX   DOI=10.15114/tr.35.25;
RA   Yonekura N., Yokosawa N., Hariya Y., Dehari H., Kohama G.-i.,
RA   Fujii N.;
RT   "Interferon-alpha and interferon-gamma augment apoptosis in oral
RT   carcinoma cells treated with Shiga toxin 2 (Stx2).";
RL   Tumor Res. 35:25-33(2000).
//
RX   PubMed=9119748; DOI=10.1111/j.1349-7006.1997.tb00365.x;
RA   Miyazaki A., Sato N., Takahashi S., Sasaki A., Kohama G.-i.,
RA   Yamaguchi A., Yagihashi A., Kikuchi K.;
RT   "Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted
RT   CD4 killer T cells against human autologous squamous cell
RT   carcinoma.";
RL   Jpn. J. Cancer Res. 88:191-197(1997).
//
RX   PubMed=12716470; DOI=10.1111/j.1349-7006.2002.tb01338.x;
RA   Kondo H., Sahara H., Miyazaki A., Nabeta Y., Hirohashi Y.,
RA   Kanaseki T., Yamaguchi A., Yamada N., Hirayama K., Suzuki M.,
RA   Hamuro J., Torigoe T., Takahashi N., Kohama G.-i., Ikeda H., Sato N.;
RT   "Natural antigenic peptides from squamous cell carcinoma recognized by
RT   autologous HLA-DR8-restricted CD4+ T cells.";
RL   Jpn. J. Cancer Res. 93:917-924(2002).
//
RX   PubMed=19123955; DOI=10.1186/1479-5876-7-1;
RA   Kobayashi J.-i., Torigoe T., Hirohashi Y., Idenoue S., Miyazaki A.,
RA   Yamaguchi A., Hiratsuka H., Sato N.;
RT   "Comparative study on the immunogenicity between an HLA-A24-restricted
RT   cytotoxic T-cell epitope derived from survivin and that from its
RT   splice variant survivin-2B in oral cancer patients.";
RL   J. Transl. Med. 7:1.1-1.11(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//